Efficacy and safety of sequential hyperthermic intraperitoneal chemotherapy following surgery for pathological T staging 4 gastric cancer

Table 1 General patient characteristics, n (%)/mean ± SD/mean (interquartile range)

Characteristic	Before PSM				After PSM
	HIPEC + AC group (n = 96)	AC group (n = 129)	P value	SMD	HIPEC + AC group (n = 80)	AC group (n = 80)	P value	SMD
Sex			0.060				0.587
Male	75 (78.12)	86 (66.67)		-0.243	61 (76.25)	58 (72.50)		-0.084
Female	21 (21.88)	43 (33.33)		0.243	19 (23.75)	22 (27.50)		0.084
Age	60.00 (53.00, 67.25)	65.00 (58.00, 71.00)	< 0.001	0.479	61.50 (55.00, 69.00)	65.00 (55.75, 70.00)	0.299	0.126
Body mass index	21.63 ± 3.21	21.89 ± 3.21	0.550	0.081	21.76 ± 3.22	22.08 ± 3.34	0.546	0.094
Tumor location			0.022				0.884
Upper	27 (28.12)	60 (46.51)		0.369	25 (31.25)	29 (36.25)		0.104
Middle	23 (23.96)	20 (15.50)		-0.234	19 (23.75)	16 (20.00)		-0.094
Lower	45 (46.88)	46 (35.66)		-0.234	35 (43.75)	34 (42.50)		-0.025
Anastomotic site	1 (1.04)	3 (2.33)		0.085	1 (1.25)	1 (1.25)		0.000
Tumor differentiation			0.793				0.668
High-grade	78 (81.25)	103 (79.84)		-0.035	66 (82.50)	68 (85.00)		0.070
Low-grade	18 (18.75)	26 (20.16)		0.035	14 (17.50)	12 (15.00)		-0.070
Pathological T staging			0.897				0.755
T4a	89 (92.71)	119 (92.25)		-0.017	74 (92.50)	75 (93.75)		0.052
T4b	7 (7.29)	10 (7.75)		0.017	6 (7.50)	5 (6.25)		-0.052
Pathological N staging			0.038				0.598
N0	9 (9.38)	25 (19.38)		0.253	9 (11.25)	7 (8.75)		-0.088
N+	87 (90.62)	104 (80.62)		-0.253	71 (88.75)	73 (91.25)		0.088

AC: Adjuvant chemotherapy; HIPEC: Hyperthermic intraperitoneal chemotherapy; PSM: Propensity score matching; SMD: Standardized mean difference.